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ABSTRACT: Aminoglycosides (AGs) are broad-spectrum antibiotics used for the
treatment of serious bacterial infections but have use-limiting side effects including
irreversible hearing loss. Here, we assessed the otoprotective profile of carvedilol in
mouse cochlear cultures and in vivo zebrafish assays and investigated its mechanism of
protection which, we found, may be mediated by a block of the hair cell’s
mechanoelectrical transducer (MET) channel, the major entry route for the AGs. To
understand the full otoprotective potential of carvedilol, a series of 18 analogues were
prepared and evaluated for their effect against AG-induced damage as well as their
affinity for the MET channel. One derivative was found to confer greater protection than carvedilol itself in cochlear cultures
and also to bind more tightly to the MET channel. At higher concentrations, both carvedilol and this derivative were toxic in
cochlear cultures but not in zebrafish, suggesting a good therapeutic window under in vivo conditions.
■ INTRODUCTION
Aminoglycosides (AGs) are broad-spectrum antibiotics widely
prescribed to treat severe bacterial infections.1−3 Despite being
highly efficacious, they cause unfortunate side effects such as
reversible nephrotoxicity and irreversible hearing loss, with the
latter occurring in up to 25% of treated patients.4 The AGs can
enter the sensory hair cells of the inner ear through both
endocytic processes5 and specialized cation channels, the
mechanoelectrical transducer (MET) channels that are located
at the tips of the stereocilia and are responsible for the
detection of sounds and body movements.6−9 The mechanism
of ototoxicity is not fully understood and it differs amongst the
various AGs, with neomycin and gentamicin, for instance,
being shown to activate different cell-death pathways once
inside zebrafish lateral line hair cells.10−12 Once inside the cell,
they are thought to interact with various targets such as
ribosomes, the endoplasmic reticulum, and mitochondria,13,14
leading to the production of cytotoxic levels of reactive oxygen
species (ROS) which, in turn, cause apoptosis.15 It is this AG-
induced hair cell death that underlies the hearing loss
associated with clinical drug treatments. Aside from the
redesign of novel AGs16,17 or hair cell regeneration
approaches,18 methods aimed at preventing this use-limiting
side effect have primarily focused on either preventing the
entry of AGs into hair cells by identifying blockers of the MET
channel14 or by reducing the cellular accumulation of ROS,
often by application of antioxidants, in an attempt to prevent
the induction of apoptosis.14,19 Recent efforts in this field have
led to the identification of otoprotective agents able to reduce
or prevent the AG-induced hearing loss both in in vitro20−23
and in in vivo models of AG ototoxicity.24
Here, we investigated the otoprotective potential of
carvedilol, an FDA-approved nonselective α1- and β-
adrenergic blocker (Figure 1), used clinically for the treatment
of hypertension, angina, and symptomatic chronic heart failure.
Carvedilol has previously been reported to protect against
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Figure 1. Structure of carvedilol, a nonselective α1- and β-adrenergic
blocker.
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neomycin damage in lateral line hair cells of zebrafish when
tested at 10 μM against 200 μM neomycin.22 In addition,
carvedilol did not abrogate the antimicrobial properties of
neomycin, making any interference with the bactericidal
activity of AGs unlikely22 and making it an ideal chemical
starting point for further investigation.
In this study, we report its protective properties against
gentamicin-induced hair cell damage in mouse cochlear
cultures. We propose the mechanism by which it offers
otoprotection with data supporting the block of the MET
channel as being responsible for its otoprotective effect. We
synthesized and evaluated a series of novel carvedilol
derivatives aimed at improving the protective efficacy and
affinity for the MET channel, whilst concurrently reducing
toxicity.
■ RESULTS
Carvedilol Protects Mammalian Sensory Hair Cells
from Gentamicin Damage. Mouse cochlear cultures were
used to assess whether carvedilol can protect mammalian hair
cells from the death induced by exposure to 5 μM gentamicin
for 48 h. A concentration of 5 μM gentamicin is optimal, as it
is close to the estimated concentration of 1 μM gentamicin
reached in the endolymph in vivo at the onset of ototoxic
symptoms,25 and it kills >90% of the basal cells while sparing
the apical cells, consistent with the predominantly high-
frequency hearing loss observed in patients treated with AGs.4
On an average, incubation with 5 μM gentamicin caused a loss
of 86% of outer hair cells (OHCs) from the mid-basal region
of the cochlea, with 110 ± 2.2 (n = 26) OHCs present in a 300
μm long segment of the control and only 15 ± 2.2 (n = 26) in
the gentamicin-treated culture (p < 0.001) (Figure 2A,B).
Subsequently, mouse cochlear cultures were coincubated with
5 μM gentamicin together with escalating concentrations of
carvedilol with the aim to identify the minimal concentration
required to provide full protection. When tested at 5 μM,
carvedilol provided partial protection, with OHC survival
differing significantly from that in both the control and
gentamicin-only treated cultures (p < 0.001 in both cases),
suggesting that this concentration is at the limit of its
protective efficacy (Figure 2C). When tested at 10 and 20
μM, carvedilol provided complete protection against the
gentamicin-induced loss of OHCs (p < 0.001) (Figure 2D,E,
respectively). Higher concentrations of carvedilol (≥30 μM)
proved to be generally cytotoxic, with widespread cell death
observed (Figure 2F).
When carvedilol was tested alone, no OHC death was
observed at either 10 or 20 μM, with hair cell numbers similar
to those observed in controls (Figure 3A−D). Some degree of
inner hair cell (IHC) damage and disruption to hair bundle
morphology in both IHCs and OHCs can be observed when
tested at 20 μM both alone and in combination with 5 μM
gentamicin (Figures 2E and 3D). Figure 3E,F shows confocal
images of IHC stereociliary bundles in control conditions
(Figure 3E) and after exposure to 20 μM carvedilol (Figure
3F), revealing the full extent of morphological disruption
caused by carvedilol.
At concentrations ≥ 30 μM, carvedilol is generally cytotoxic
to all cell types in cochlear cultures, both alone and in the
presence of 5 μM gentamicin (Figures 2F and 3G,H). Figure
3I summarizes the quantification of OHC survival through
analysis of the mid-basal region of cochlear cultures for both
carvedilol alone and also coexposed with gentamicin.
Carvedilol Exerts Its Otoprotective Effect by Acting
as a Permeant Blocker of the Hair Cell’s MET Channel.
Despite a narrow therapeutic window in vitro, we decided to
investigate the potential mechanism by which carvedilol
Figure 2. Protective effect of carvedilol against gentamicin-induced
damage in a mouse cochlear culture assay. Control cultures exposed
to either 0.5% DMSO (A) or 5 μM gentamicin + 0.5% DMSO (B) for
48 h. When coincubated with 5 μM gentamicin, carvedilol was found
to be partially protective at 5 μM (C), fully protective at 10 and 20
μM (D,E respectively), and generally cytotoxic at ≥30 μM (F). The
asterisk in (E) indicates an example of IHC hair bundle disruption.
Scale bar is 50 μm.
Figure 3. Carvedilol disrupts mechanosensory hair bundles at 20 μM
and is generally cytotoxic in vitro at ≥30 μM. Cochlear cultures were
exposed for 48 h to 0.5% DMSO (A,E), 5 μM gentamicin + 0.5%
DMSO (B), and escalating concentrations of carvedilol: 10 (C), 20
(D,F), 30 (G), and 40 μM (H). Scale bar is 10 (F) and 50 μm (H).
Quantification of hair cell survival in a 300 μm long segment of the
mid-basal region of cochlear cultures is reported in (I).
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provides its protective effect. It is well established that AGs can
enter hair cells via their MET channels7,9 and that block of this
channel reduces or prevents their entry into the cells, thereby
protecting them from any toxicity resulting from intracellular
accumulation. To determine whether carvedilol protects via an
interaction with the MET channel, we recorded MET currents
from OHCs both before and during extracellular superfusion of
carvedilol at concentrations of 1, 3, and 10 μM.
Figure 4A shows an example of the MET currents recorded
before (black), during (red), and after (blue) exposure to
carvedilol (10 μM), at membrane potentials ranging from
−164 to +96 mV. Carvedilol reduces the size of MET currents
at all membrane potentials, with this reduction particularly
pronounced at intermediate and depolarized potentials. Upon
re-exposure to the control solution, the currents recover,
indicating a reversible block of the channel. The voltage-
dependent block and subsequent recovery of the currents can
also be clearly seen from the current−voltage relationships as
shown in Figure 4B.
Average normalized current−voltage relationships derived
from all cells recorded from at the three different
concentrations tested, normalized to the maximum control
current at +96 mV for each cell, demonstrated both the
increase in the block with increasing compound concentration
and the voltage-dependence of the block, with the strongest
block observed at the intermediate and depolarized potentials
(Figure 5A).
Some recovery of the currents can be seen at the extreme
depolarized potentials (+96 mV), with even more pronounced
recovery at the extreme hyperpolarized potentials (−164 mV).
This recovery with hyperpolarization is more evident from the
average fractional block curves showing the current during
carvedilol superfusion relative to the control current at each
membrane potential (Figure 5B). The maximum block is seen
at the intermediate membrane potentials for each concen-
tration of carvedilol with some recovery at depolarized
potentials and even greater recovery at the extreme hyper-
polarized potentials. This recovery at the hyperpolarized
potentials is indicative of a permeant blocker with the
Figure 4. Extracellular exposure to carvedilol reduces OHC MET currents at all potentials, with the reduction most pronounced at intermediate
and depolarized potentials. (A) MET currents recorded from a basal-coil OHC between −164 and +96 mV before, during, and after exposure to 10
μM carvedilol. (B) Current−voltage relationships of the currents shown in A reveal the current block at all potentials during carvedilol exposure
and the reversibility of the block following washout. The capacitance of the cell was 7.4 pF.
Figure 5. Carvedilol acts as a relatively high-affinity permeant blocker of the MET channel. (A) Average normalized current−voltage relationships
for the peak MET currents recorded before and during exposure to 1, 3, and 10 μM carvedilol with currents normalized to the peak control current
measured at +96 mV for each cell. (B) Fractional block curves of the current during carvedilol exposure (1, 3, and 10 μM) relative to the control
current at each membrane potential. Data are fitted with two barrier−one binding site model (see the Experimental Section). Parameters for the fits
are ΔE (the difference in free energy between the intracellular and extracellular barrier) −0.63kT; Eb (the free energy of the binding site) −15.4kT;
δb (the electrical distance of the binding site from the extracellular side) 0.53; z (the electrical charge of the blocker) 1.0; Hill coefficient 1.0.
Maximum block occurs at +12.8 mV. (C) Dose−response curves derived from the currents recorded at −164, +16, and +96 mV and fit with eq 1.
−164 mV: KD 6.3 μM, Hill coefficient 1.1; +16 mV: KD 0.1 μM, Hill coefficient 0.5; +96 mV: KD 1.5 μM, Hill coefficient 0.9. (D) Values of the
half-blocking concentration and Hill coefficient at each membrane potential.
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compound, positively charged at physiological pH (calculated
pKa = 8.7), being drawn into the cell by the electrical driving
force and therefore reducing the block of the channel. Curves
are fitted to a two barrier−one binding site model of the MET
channel permeation pathway. Dose−response curves for the
extracellular block of the MET channels by carvedilol were
generated at each membrane potential and fitted with eq 1
described in the Experimental Section. The dose−response
curves derived from the currents at −164, +16, and +96 mV
are shown in Figure 5C. The KD values range from 6.3 μM at
−164 mV to 0.1 μM at +16 mV, close to the potential at which
the block was strongest (+12.8 mV). The KD at −84 mV was
2.0 μM, lower than that previously reported for the AG
dihydrostreptomycin (DHS), which was found to have a KD of
7.0 μM at −84 mV in 1.3 mM extracellular Ca2+,7 indicating
that carvedilol is a relatively high affinity blocker of the MET
channel. Figure 5D reports the KD and Hill coefficient values
for each dose−response curve showing the strongest
interaction near +16 mV. The Hill coefficients ranged from
0.5 to 1.3, suggesting that two molecules may interact with the
channel, potentially showing negative cooperativity.26
These results demonstrate that carvedilol is a relatively high-
affinity permeant blocker of the MET channel and consistently
protects OHCs from AGs damage at 10 and 20 μM. However,
in vitro, it appears to be cytotoxic at higher concentrations.
Chemistry. Driven by these results, we decided to
investigate the potential of carvedilol as the chemical starting
point for future drug development. We aimed at enhancing its
protective effect in mouse cochlear cultures, increasing its
block of the MET channel current and reducing the
cytotoxicity observed in vitro. We decided to investigate its
structure by modifying the carbazole moiety, the anisole ring,
and the β-hydroxyl amino group. We first synthesized
compound 2 by substituting the carbazole with anisole. The
Scheme 1a
aReagents and conditions: (i) 2-(bromomethyl)oxirane, anhydrous K2CO3, DMF, 70 °C, 6 h; (ii) 2-(2-methoxyphenoxy)ethanamine, ethylene
glycol dimethyl ether, 80 °C, 6 h; (iii) 1,2-dibromoethane, NaOH, water, reflux, 3 h; (iv) 2-(2-methoxyphenoxy)ethanamine, TEA, THF, 65 °C, 6
h.
Scheme 2a
aReagents and conditions: (i) 2-(bromomethyl)oxirane, NaOH, water, DMSO, 45 °C, 16 h; (ii) 2-phenoxyethanamine, ethylene glycol dimethyl
ether, 80 °C, 24 h; (iii) butan-1-amine, ethylene glycol dimethyl ether, 80 °C, sealed tube, 24 h; (iv) phenylpiperazine, ethanol, 65 °C, 16 h; (v) 4,
ethylene glycol dimethyl ether, 80 °C, sealed tube, 48 h.
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synthesis involved the preparation of 1 by coupling 2-
methoxyphenol and 2-(bromomethyl)oxirane followed by
epoxide ring opening with commercially available 2-(2-
methoxyphenoxy)ethanamine in ethylene glycol dimethyl
ether at 80 °C, providing the desired compound in moderate
yield (Scheme 1).
In parallel, to simplify the structure of carvedilol and likely
removing its interactions with adrenergic receptors, we
investigated the requirement for the β-hydroxyl amino group
by evaluating compound 4, which was prepared by coupling 2-
(2-methoxyphenoxy)ethanamine and 3, which was previously
made by reacting 2-methoxyphenol with 1,2-dibromoethane.
We then investigated the role of the anisole ring by
simplifying to a simple phenol 6 and an aliphatic chain 7; the
role of the basic center by inserting a cyclic tertiary amine
(phenyl-piperazinyl) 8 and a tertiary amine bearing two 2-(2-
methoxyphenoxy)ethanamine moieties 9. These compounds
are prepared starting from the common intermediate 5, which
is prepared by reacting 4-hydroxycarbazole with 2-
(bromomethyl)oxirane in good yield. The epoxide ring is
then opened by the appropriate amine using ethylene glycol
dimethyl ether as solvent for 6, 7, and 9 in moderate to good
yield, while in the case of 8, ethanol was used as solvent,
affording the desired compound in 80% yield (Scheme 2).
Scheme 3a
aReagents and conditions: (i) 1,3-dibromopropane for 10, 1,4-dibromobutane for 11, 1,6-dibromohexane for 12, KOH, acetonitrile, rt, 5-18 h; (ii)
2-(2-methoxyphenoxy)ethanamine, anhydrous K2CO3, DMF, rt, 16 h for 13; 2-(2-methoxyphenoxy)ethanamine, TEA, THF, 65 °C, 24 h for 14;
(iii) 2-methoxyphenol, KOH, acetonitrile, rt, 66 h; (iv) 4, K2CO3, DMF, rt, 36 h; (v) ethyl chloroacetate, K2CO3, acetone, reflux, 16 h; (vi) 1 N
aqueous NaOH, THF, rt, 16 h; (vii) 2-(2-methoxyphenoxy)ethanamine, HOBt, EDC·HCl, DIPEA, DMF, rt, 16 h.
Scheme 4a
aReagents and conditions: (i) 2-(bromomethyl)oxirane, sodium hydroxide, water, DMSO, 45 °C, 16 h; (ii) 2-(2-methoxyphenoxy)ethanamine,
ethanol, 65 °C, 16 h; (iii) 2-(bromomethyl)oxirane, potassium hydroxide, acetonitrile, rt, 20 h; (iv) 2-phenylethylamine, ethanol, 65 °C, 16 h; (v)
4-(2-aminoethyl)morpholine, TEA, THF, 65 °C, 4 h; (vi) 4-(oxiran-2-ylmethoxy)-9H-carbazole, ethanol, 65 °C, 16 h.
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We then investigated the role of the hydroxyl group by
preparation of 13, the carbazole-amine linker 14, removing the
β-hydroxyl amine by linking the carbazole and the anisole rings
via a six carbon chain 15 and removing the basic center by the
introduction of an amidic bond 19. Based on the biological
data obtained with compounds 9 and 13, we combined these
modifications to make compound 16. For the synthesis, 4-
hydroxycarbazole was reacted with either 1,3-dibromopropane,
1,4-dibromobutane, or 1,6-dibromohexane to give compounds
10−12, respectively. Compounds 10 and 11 were coupled with
2-(2-methoxyphenoxy)ethanamine, yielding 13 and 14, while
compound 12 was coupled with 2-methoxyphenol to give 15 in
moderate yield. Compound 16 was obtained by coupling 10
with 4. For the preparation of the amide analogue 19, 4-
hydroxycarbazole was reacted with ethyl chloroacetate to
afford ester 17, which was hydrolyzed with aqueous sodium
hydroxide providing acid 18. Coupling with 2-(2-
methoxyphenoxy)ethanamine was performed under standard
amide coupling conditions using 1-hydroxybenzotriazole
(HOBt) and N-(3-dimethylaminopropyl)-N′-ethylcarbodii-
mide (EDC) affording the desired compound 19 in good
yield (Scheme 3).
We then investigated two isomers of carvedilol: 2-
hydroxycarvedilol derivative 21, which was obtained by
opening the epoxide ring of compound 20 with 2-(2-
methoxyphenoxy)ethanamine, providing the desired com-
pound 21 in moderate yield (Scheme 4); and the 1-carbazole
isomer by directly linking the side chain to the nitrogen of the
carbazole ring. First, carbazole reacted with epichlorohydrin to
yield compound 22 followed by epoxide ring opening using 2-
phenylethylamine, obtaining compound 23 in 49% yield.
Finally, to improve the solubility of compound 9, we
designed compound 25 in which one of the 2-methoxyphenoxy
group was substituted with a morpholine ring. Compound 3
was reacted with commercially available 4-(2-aminoethyl)-
morpholine to obtain compound 24 which was then coupled
with 5 to give the desired compound 25 in 29% yield.
Carvedilol Derivatives: Protective Abilities and MET
Channel Block. The newly synthesized compounds were
screened to assess their protective ability against 5 μM
gentamicin using mouse cochlear cultures initially at 20 μM, a
concentration at which carvedilol provided full protection and
was not cytotoxic. Any compounds that showed full or partial
protection were then screened at lower concentrations to
establish their minimal protective concentration. We initially
designed and synthesized 6 compounds aimed at evaluating the
chemical moiety essential for the interaction with the MET
channel, and these include modification at the carbazole (2 and
4) and anisole (6 and 7) rings, the removal of the hydroxyl
group (13), and the introduction of a second 2-phenoxyethyl
moiety to form a tertiary amine (9). When tested at 20 μM
(Figure 6), compounds 2 and 4 lacking the carbazole moiety
provided no protection (Figure 6C,D), while compound 6
with a phenyl group instead of the anisole proved to be
generally cytotoxic (Figure 6E). Compound 9, bearing two 2-
methoxyphenoxyethyl moieties, offered only partial protection
(Figure 6G), while compounds 7 and 13 consistently
protected against OHC loss (Figure 6F,H). As a reference,
control cochlear cultures exposed to 0.5% dimethyl sulfoxide
(DMSO, Figure 6A) and 5 μM gentamicin (Figure 6B) as well
as quantification for both controls and cultures exposed to
compounds (Figure 6I) are included.
The three derivatives (7, 9, and 13) that showed partial or
full protection at 20 μM were subsequently tested at 10 and 5
μM against 5 μM gentamicin. Only compound 13 provided full
protection at 5 μM (as well as at 10 μM), showing an
improvement compared to the parent compound carvedilol
which was only partially protective at 5 μM (Figure 7A−E). As
stated before, in the control condition, some 110 OHCs were
present in each cochlear segment, reducing to 15 OHCs
following exposure to 5 μM gentamicin. Additional exposure to
5 μM carvedilol increased the average number of surviving
OHCs to 66 (54% protection), whereas 5 μM compound 13
resulted in 99 surviving OHCs (88% protection) (Figure 7E).
When tested alone, 13 showed similar toxicity characteristics
to carvedilol, proving toxic to OHCs at concentrations ≥ 30
μM and affecting the IHC and OHC bundle morphology at 20
μM. Contrary to carvedilol, 13 was not toxic at 30 μM when
tested together with 5 μM gentamicin, but it did also affect the
IHC and OHC bundle morphology (data not shown).
In conjunction with assessing the protective abilities of these
six compounds, potential interactions with the MET channel
were investigated by recording MET currents from OHCs
before and during exposure to 10 μM of each compound.
Figure 8 shows the fractional block of the currents during
compound exposure relative to the control currents at each
membrane potential, revealing that two compounds 4
Figure 6. Otoprotective effect of compounds 2, 4, 6, 7, 9, and 13 in
cochlear cultures against 5 μM gentamicin. (A) Control culture
exposed to 0.5% DMSO for 48 h. (B) Culture exposed to 5 μM
gentamicin + 0.5% DMSO for 48 h. (C−H) Cultures exposed to 5
μM gentamicin for 48 h + 20 μM: (C) 2, (D) 4, (E) 6, (F) 7, (G) 9,
and (H) 13. Scale bar is 50 μm. (I) Quantification of OHC survival
for the control and compound exposed cultures.
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(magenta) and 2 (blue) have limited interaction with the
channel at this concentration.
The poor interaction of compounds 2 and 4 with the MET
channel corresponded to the lack of protection observed for
these compounds at 20 μM, providing further evidence that
the protection offered by carvedilol may come through a block
of the MET channel. In addition, these results indicate the
need for the carbazole moiety to allow the interaction with the
channel. Compound 9 (bright green), which offered only a
partial protection at 20 μM, showed approximately 40% block
of the MET current at all membrane potentials with no release
at extreme hyperpolarized potentials, suggesting this com-
pound may act as a non-permeant blocker. Compounds 6
(red) and 7 (orange) were strong MET channel blockers at 10
μM with a blocking profile similar to carvedilol giving
approximately 50−60% block of the current at −164 mV,
the most relevant physiological potential. Interestingly,
compound 13 (dark green) was the most effective MET
channel blocker of this series, providing almost 100% block of
the MET current at all membrane potentials. This result is also
in accordance with its protective effect, as 13 showed
protection of the OHCs from gentamicin damage at
concentrations down to 5 μM. This result again suggests that
the protection observed is due to a block of the MET channels,
reducing the entry of gentamicin into the cells. Compounds 6,
7, and 13 appear to be permeant blockers of the MET channel,
indicated by the release of the block at the extreme
hyperpolarized potentials, and in the case of compound 13,
the release of the block was less pronounced than with
carvedilol itself.
A further seven compounds (8, 14, 15, 19, 21, 23, and 25)
were then designed and synthesized in an attempt to improve
protective abilities and physicochemical properties. Of these,
14, 15, 21, and 23 were generally cytotoxic when tested at 20
μM against 5 μM gentamicin (Figure 9D,E,H,I, respectively),
19 and 8 offered no protection (Figure 9C,G, respectively),
and 25 was consistently protective (Figure 9J). When tested at
10 μM, 25 was protective in 2 out of 4 screens but offered no
protection at 5 μM (data not shown). MET channel
interactions were subsequently investigated for derivative 25
that showed protection at 20 μM and partial protection at 10
Figure 7. When tested at 5 μM against 5 μM gentamicin, compound
13 showed a greater otoprotective effect. (A) Control culture exposed
to 0.5% DMSO for 48 h. (B) Culture exposed to 5 μM gentamicin +
0.5% DMSO for 48 h. (C,D) Cultures exposed to 5 μM gentamicin
for 48 h + 5 μM: (C) carvedilol or (D) compound 13. Scale bar is 50
μm. (E) Quantification of OHC survival for the control and
compound-exposed cultures.
Figure 8. Compounds 2, 4, 6, 7, 9, and 13 show varying degrees of
inhibition of the MET currents. Fractional block plots of the currents
recorded during exposure to 10 μM of each derivative relative to the
control currents at each membrane potential.
Figure 9. Otoprotective effect of compounds 8, 14, 15, 16, 19, 21, 23,
and 25 in cochlear cultures against 5 μM gentamicin. (A) Control
culture exposed to 0.5% DMSO for 48 h. (B) Culture exposed to 5
μM gentamicin + 0.5% DMSO for 48 h. (C−J) Cultures exposed to 5
μM gentamicin for 48 h + 20 μM: (C) 8, (D) 14, (E) 15, (F) 16, (G)
19, (H) 21, (I) 23, and (J) 25. Scale bar is 50 μm. (K) Quantification
of hair cell survival for the control and cultures exposed to
compounds.
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μM. The resulting fractional block plot reveals that at a
concentration of 10 μM, 25 blocks the MET channel at all
membrane potentials (Figure 10). However, the degree of the
block is far less than that observed for carvedilol and 13
suggesting this derivative has a reduced affinity for the channel.
Combining the desired characteristics of a nonpermeant
MET channel blocker (9) with a high-affinity blocker (13), we
designed, synthesized, and tested a further derivative (16).
This compound was found fully protective at 20 μM against 5
μM gentamicin on only one out of three occasions (Figure
9F), with no protection in the other two trials. The lack of
consistency with the data was probably caused by the poor
solubility of the compound. When tested at 10 μM, compound
16 did not offer any protection (data not shown). When tested
in our electrophysiology assay, compound 16 showed limited
interaction with the MET channel at both 3 and 10 μM (data
not shown).
Assessing the Protective Effect and MET Channel
Properties of Adrenergic Receptor and Calcium
Channel Blockers.We then proceeded to investigate whether
the adrenergic (α and β) receptors, primary pharmacological
targets of carvedilol, play a role in its otoprotective abilities. We
tested the nonselective β-blocker propranolol 26, the selective
β1-blocker CGP20712 27, the selective α1-blocker naftopidil
28, and the nonselective adrenergic blocker and calcium
channel-blocker verapamil 29 (Figure 11).
Compounds 26, 27, and 29 did not offer any protection
against 5 μM gentamicin when tested at 20 μM (Figure
12C,D,F, respectively), while 28 proved to be partially effective
under the same conditions (Figure 12E,G). However, when
the test concentration was lowered to 10 μM, compound 28
did not protect cochlear culture hair cells against gentamicin
damage (data not shown).
We subsequently investigated the affinity of the partially
protective compound 28 for the MET channel. This
compound did not interact strongly with the MET channel
which is revealed from the fractional block plot shown in
Figure 13.
Electrophysiological Properties of Compound 13: A
Strong Permeant MET Channel Blocker. The cochlear
culture protection assay revealed that carvedilol derivative 13,
at a concentration of 5 μM, displayed a consistent protective
effect against 5 μM gentamicin. When tested on its own,
Figure 10. Fractional block plot for compound 25 (10 μM). The size
of the current during exposure to the compound relative to the
control current at each membrane potential reveals that compound 25
has a low affinity for the MET channel.
Figure 11. Chemical structures of other adrenergic blockers (26−28) and calcium channel-blocker 29 used in this study.
Figure 12. Otoprotective effect of compounds 26, 27, 28, and 29 in
cochlear cultures against 5 μM gentamicin. (A) Control culture
exposed to 0.5% DMSO for 48 h. (B) Culture exposed to 5 μM
gentamicin + 0.5% DMSO for 48 h. (C−F) Cultures exposed to 5 μM
gentamicin for 48 h + 20 μM: (C) 26, (D) 27, (E) 28, and (F) 29.
(G) Quantification of hair cell survival for the control and compound
exposed cultures. Scale bar is 50 μm.
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compound 13 appears to be cytotoxic at 30 μM. However,
when tested in the presence of 5 μM gentamicin, compound
13 is not toxic, suggesting a competitive interaction at the level
of the MET channel that may effectively reduce the cytotoxic
effects of both compounds. In order to compare MET channel
interactions between compound 13 and carvedilol, MET
currents were recorded before and during 13 exposure at 1, 3,
and 10 μM and the resulting current−voltage relationships,
fractional block curves, and dose−response curves generated
(Figure 14).
From the average normalized current−voltage relationships
(Figure 14A) and the fitted average fractional block curves
(Figure 14B) it can be seen that the block of the channel by 13
is very similar to that of carvedilol, with the maximum block
seen at the intermediate potentials and release of the block at
extreme depolarized and hyperpolarized potentials, indicating
that this compound is also a permeant blocker of the MET
channel. Dose−response curves were generated, derived from
the currents at each membrane potential, and fitted with eq 1
(see Experimental Section). Figure 14C shows the curves
derived from the currents at −164, +16, and +96 mV, where
the KD values were found to be 4.6, 1.0, and 1.7 μM,
respectively. The KD at −84 mV (2.4 μM) is similar to that of
carvedilol (2.0 μM), suggesting that both compounds are
relatively high affinity blockers of the MET channel at a
potential close to the resting potential in vitro. The Hill
coefficients ranged from 1.1 to 2.0, suggesting there may be
two or more binding sites within the channel for 13 (Figure
14D).26
Kinetics of MET Channel Block for Carvedilol and
Compound 13. One further property of the MET channel
interaction that was investigated for both carvedilol and 13 was
the kinetics of the block, to determine whether or not these
compounds are open-channel blockers, similar to berbamine
and D-tubocurarine,20 or can reside in the closed channel,
similar to the permeant MET channel blocker FM1-43.6 The
time course of the block is revealed by applying large force
steps to the hair bundles both before and during exposure to
the compound and recording the resulting currents. Such
currents can be seen before and during exposure to carvedilol
(1 and 3 μM; Figure 15A,B) and 13 (1 and 3 μM; Figure
15C,D). From a holding potential of −84 mV, channel
opening results in rapidly activating inward currents in all
conditions. During the step, the currents show minimal
adaptation in control conditions and an exponential decline
during both carvedilol and 13 exposure. This suggests that
both compounds are open-channel blockers, accessing their
binding site once the channel has opened. Time constants were
measured from the current decline and found to be 18.0 ± 5.0
ms (1 μM carvedilol; n = 3); 9.6 ± 0.4 ms (3 μM carvedilol; n
= 4); 9.9 ± 0.9 ms (1 μM 13; n = 3); and 6.0 ± 1.6 ms (3 μM
13; n = 3).
Figure 13. Fractional block plot for compound 28. The size of the
current during exposure to the compound relative to the control
current at each membrane potential reveals that compound 28 has a
low affinity for the MET channel.
Figure 14. Compound 13 acts as a permeant blocker of the MET channel, with similar blocking properties to carvedilol. (A) Average normalized
current−voltage relationships for the peak MET currents recorded before and during exposure to 1, 3, and 10 μM 13. (B) Fractional block curves
for compound 13 tested at 1, 3, and 10 μM reveal that it is a permeant MET channel blocker. Fitting parameters are ΔE −2.22kT; Eb −21.3kT; δb
0.71; z 1.0; δb 0.71; Hill coefficient 1.4. Maximum block occurs at +33.9 mV. (C) Dose−response curves derived from the currents recorded at
−164, +16, and +96 mV and fit with eq 1. −164 mV: KD 4.6 μM, Hill coefficient 1.6; +16 mV: KD 1.0 μM, Hill coefficient 2.0; +96 mV: KD 1.7 μM,
Hill coefficient 1.4. (D) Half-blocking concentration and Hill coefficient as a function of membrane potential.
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From these time constants, entry rates of the drug molecules
into the hair cells were calculated (see the Experimental
Section), and their energy profiles for permeation through the
MET channel pore were determined (Figure 16). Both
compounds bind much stronger (free energy Eb < −15kT)
to the binding site in the channel pore than DHS (Eb −8.27kT
at 1.3 mM extracellular Ca2+)7 and the drugs D-tubocurarine
(−8.67kT) and berbamine (−12.0kT) that we evaluated
before.20 A consequence of this is that, unlike the other
compounds, the maximum block for these monovalent cations
(at physiological pH) occurs at positive membrane potentials
(Figures 5B and 14B). Moreover, their permeation through the
MET channels is considerably slower than DHS. For example,
with 1 μM of compound, 80 MET channels with an open
probability of 0.1 and a membrane potential of −150 mV, the
entry rates into the OHCs are 165 molecules/s for carvedilol
and 125 molecules/s for 13, compared with some 1130
molecules/s for DHS.7,20 For higher concentrations, the entry
rates started to saturate, so they never approach those for DHS
(e.g., for 100 μM, rates were 1078 molecules/s for carvedilol,
998 molecules/s for 13, and 11 460 molecules/s for DHS).
Carvedilol and Compound 13 Reduce GTTR Loading
into Hair Cells. To further assess whether carvedilol and 13
protect sensory hair cells against AG damage by preventing the
entry of the antibiotics into cells, a fluorescent gentamicin
analogue (gentamicin Texas Red: GTTR) was used to enable
quantification of gentamicin uptake.27 Pre-incubation with
either 1% DMSO, 100 μM carvedilol or 100 μM 13 for 5 min
prior to 0.2 μM GTTR application resulted in significantly
reduced loading of GTTR in the presence of both carvedilol
and 13 relative to the DMSO control (p < 0.001 in both cases)
(Figure 17). A significant difference was not observed between
the GTTR loading in the presence of carvedilol or 13. These
findings further suggest that both carvedilol and 13 protect
against AG damage by competitively blocking the MET
channel and thereby preventing AG entry into hair cells,
minimizing accumulation and consequent apoptosis induction.
Comparison of Protection and Toxicity of Carvedilol
with Compound 13 in Zebrafish Larvae. In order to
compare the protective effect of 13 to that of carvedilol in vivo,
4 days post fertilization (dpf) zebrafish larvae were treated with
either neomycin or gentamicin in the presence of each
compound, and the number of remaining hair cells was
assessed (Figure S1A−D). Dose−response curves for
carvedilol and compound 13 were constructed, and EC50s
(the effective concentration at which 50% of hair cells survive)
were derived. The EC50s for carvedilol and 13 protection
against neomycin damage were 2.47 and 2.08 μM, respectively.
The EC50 for carvedilol protection against gentamicin damage
was 10.95 μM, whilst for compound 13, it was 10.81 μM. The
protective effect of these compounds therefore extends to
other AGs in addition to gentamicin.
We then assessed the toxicity of carvedilol and compound
13 by treating 3 dpf zebrafish larvae with each at 30 and 100
μM for 48 h (see the Supporting Information Methods). At a
concentration of 100 μM, carvedilol killed the larvae in two out
of three trials, whilst it was not toxic at 30 μM. With
compound 13, neither concentration was toxic for the larvae.
Larvae treated with 100 μM carvedilol had slowed or no
circulation, while those treated with 30 μM of carvedilol or
either concentration of compound 13 had no obvious defects
in circulation. Treated larvae were startled and assayed for
movement. As expected, larvae treated with 100 μM carvedilol
showed reduced movement, whilst those treated with 100 μM
of compound 13 showed increased movement compared to
the control.
Assessing Effects of Carvedilol and Compound 13 on
the Antimicrobial Efficacy of Gentamicin. Carvedilol and
compound 13 were tested in a bacterial cell viability assay to
identify if either of these compounds decreased the
antimicrobial activity of gentamicin. The minimum inhibitory
Figure 15. Kinetics of MET channel block mediated by carvedilol and
13 reveals that both act as open-channel blockers. (A−D) Currents
resulting from a mechanical step delivered by the fluid jet (±40 V
driver voltage, DV shown above each trace), from a holding potential
of −84 mV, before (black trace) and during (red trace) superfusion of
(A) 1 μM carvedilol, (B) 3 μM carvedilol, (C) 1 μM 13, and (D) 3
μM 13. Currents (averaged from 10 repetitions) before and during
compound exposure have been scaled and superimposed. The
currents during compound superfusion were fitted with single
exponentials (A) τ = 19.3 ms, (B) τ = 8.6 ms, (C) τ = 10.1 ms,
and (D) τ = 6.9 ms.
Figure 16. Energy profiles for MET channel permeation and block by
carvedilol and 13. Energy profiles calculated from fits to the fractional
block curves and kinetics of MET current block are shown. Values for
the free energies of the binding site Eb and barriers E1 and E2 are
shown in the absence of a voltage across the membrane (Vm = 0 mV).
The voltage-independent extracellular barrier E1, at an electrical
distance of zero, has a free energy of 12.5kT for carvedilol and 7.23kT
for 13. The free energy of Eb is −15.4kT for carvedilol and −21.3kT
for 13. The binding sites, δb, are located at an electrical distance from
the extracellular side of 0.53 for carvedilol and 0.71 for 13. The
intracellular barrier E2, positioned at an electrical distance of one, is
11.8kT for carvedilol and 5.01kT for 13. For comparison, the energy
profile calculated before for DHS in 1.3 mM extracellular Ca2+ is
shown (dotted line).7
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concentration (MIC) of gentamicin was established for three
clinically important bacteria: Klebsiella pneumoniae, Pseudomo-
nas aeruginosa, and Staphylococcus aureus. The bacteria were
treated with gentamicin at 1×MIC (2.2 μM) together with 2.2
or 11 μM carvedilol or compound 13 (1× or 5× the
gentamicin MIC). Neither of the compounds resulted in an
observable reduction in gentamicin antimicrobial activity
(Figure S2A−C).
■ DISCUSSION AND CONCLUSIONS
The nonselective α- and β-adrenergic blocker carvedilol was
reported to provide protection against AG damage in a whole
zebrafish larval model study.22 Here, we investigated its
potential using a mammalian system of AG-induced toxicity,
mouse cochlear cultures, and zebrafish larvae. In parallel, we
investigated its potential molecular target by studying its
electrophysiological profile. First, we determined that
carvedilol (10 and 20 μM) was able to fully protect cochlear
cultures against the damage caused by exposure to 5 μM
gentamicin for 48 h. Unfortunately, carvedilol proved to be
cytotoxic at higher concentrations (≥30 μM) and caused
severe damage to the mechanosensory hair bundles when
tested at 20 μM, both alone and together with gentamicin.
Despite this, we decided to investigate further the mode of
protection of carvedilol by studying its potential interaction
with the MET channel, which is the main entry route of AGs
into hair cells. From our experiments, carvedilol proved to be a
relatively high-affinity, permeant, and reversible blocker of the
MET current with a KD of 6.3 μM at a physiologically relevant
potential of −164 mV. To fully evaluate its otoprotective
profile, we decided to investigate the structure−activity
relationship (SAR) of carvedilol, aiming to improve its affinity
for the MET channel and its protective effect as well as
reducing its cytotoxicity.
From an initial investigation, we established that the
carbazole moiety is needed for both protection and interaction
with the channel, with neither compound 2 nor 4 protecting
hair cells from gentamicin or blocking the MET current.
Interestingly, the replacement of the anisole moiety with a
phenyl group as in compound 6 led to an increased
cytotoxicity while still providing the same level of block of
the MET current as its parent derivative carvedilol. The
replacement of the anisole for an alkyl chain as in compound 7
led to a retention of its protective effect and only slightly
reduced its effect on the MET current. We then investigated
the role of the β-amino alcohol linker with regard to its
interaction with the channel. The removal of the hydroxyl
group, compound 13, resulted in an almost complete block of
the MET current at 10 μM and at least the same protective
effect against gentamicin damage compared to carvedilol.
These data show that the hydroxyl group is not needed for the
interaction with the channel, and we can postulate that the
enhanced block of the channel may be derived by an increased
basicity of the nitrogen, with a calculated pKa for compound 13
and carvedilol being 9.3 and 8.7, respectively, which may lead
to a stronger interaction with the channel. To our surprise, the
extension of just one extra carbon in the alkyl chain spacer
between the carbazole and the basic center, compound 14,
proved to be detrimental as the compound was found to be
more toxic than the parent compound. The role of the basic
center was investigated by substituting the nitrogen with a
carbon (15) or by making the nitrogen nonbasic (19). Neither
of these compounds had any protective effect, supporting the
need for a basic center that is positively charged at
physiological pH for the protective effect. Also unsuccessful
was the conversion of the secondary amine into a tertiary cyclic
amine, as compound 8 did not have any protective effect
against gentamicin damage. In compound 9, we inserted a
second ethyl-anisole moiety, and it was found to interact
tightly with the channel and to act as a nonpermeant blocker as
noted by the lack of the release of the block at the extreme
hyperpolarized (−164 mV) potential, probably due to some
new interactions between the channel and the second anisole
moiety. However, the level of the block of the MET current
was reduced if compared to carvedilol, and it was only partially
protective.
We then investigated two isomers of carvedilol moving the
side chain to the 2-position (21) or linking it to the nitrogen in
the carbazole ring (23); both compounds were found to be
toxic to the cochlear cultures. Driven by the results obtained
with compounds 13 (improved protective effect and block of
the MET current) and 9 (nonpermeant MET channel
blocker), we designed compound 16, which lacks the hydroxyl
group as in compound 13 and has the second ethyl-anisole as
in compound 9. Compound 16 proved to be only partially
protective, but we noticed a lack of consistency during the
assays which is probably due to the poor solubility of this
compound in the biological media, preventing any meaningful
interpretation of the results. Whilst we solved the solubility
issue for this compound by substituting the second ethyl-
Figure 17. Carvedilol and 13 reduce the entry of GTTR into mouse cochlear culture hair cells. (A) Quantification of GTTR fluorescence intensity
in a control culture pretreated with 1% DMSO before the addition of 0.2 μM GTTR, compared to cultures pretreated with 100 μM carvedilol or
13. Both compounds significantly reduced GTTR loading (p < 0.001). No significant difference in reduction was seen between the two
compounds. (B−D) Representative fluorescence image from which intensity values were measured and a DIC image for (B,B′) the control (C,C′)
carvedilol and (D,D′) 13. Asterisks indicate the first row of OHCs, from which fluorescence intensity values were taken. N = 30 cells, with 10 cells
analyzed from three separate experiments. Scale bar is 50 μm.
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anisole moiety with an ethyl morpholine 25, this did not
translate into an increased protective effect. We then
investigated other adrenergic and calcium blockers, with
compounds 26, 27, and 29 (propranolol, CGP20712, and
verapamil, respectively) not showing any protective effect, and
28 (naftopidil) only offering partial protection at 20 μM.
Interestingly, 28 is the only compound that showed some
protection but it does not have the carbazole moiety and bears
a naphthol ring. Based on our previous findings showing D-
tubocurarine as a potent blocker of the MET channel current
(KD = 2.2 μM) without showing any toxicity at a higher
concentration (50 μM),20 the cytotoxic effect observed with
some of these compounds is unlikely to be related to their
ability to block the MET channel and is probably series related.
A hit-to-lead optimization campaign will be focused on
increasing the protective effect, reducing the toxicity, and
addressing any adrenergic effect of these compounds. In
addition, there will be the possibility of formulating the
potential otoprotective agent to allow administration into the
inner ear via transtympanic injection.
From a mechanistic point of view, we investigated in more
detail the interaction of 13, the most protective derivative, with
the MET channel. This compound showed a very similar
interaction with the channel to carvedilol, having a KD of 4.6
μM at a potential of −164 mV. Kinetics of the MET channel
block showed that both carvedilol and 13 are open-channel
blockers, suggesting that they are able to interact with the
channel only when it is open. As shown in the energy profiles
graph, both carvedilol and 13 bind tighter to the negatively
charged vestibule of the MET channel compared to the AG
DHS with a longer time consequently spent inside the channel.
This result reflects on the rate of entry into the cells for these
compounds, which is considerably lower (10 fold) compared
to DHS. This stronger interaction with the MET channel may
be behind the protective effect offered by carvedilol and 13
which hinders the interaction of AG with the channel and as a
consequence reducing its entry into the hair cells. The stronger
protection of 13 (Eb −21.3kT) compared to carvedilol may be
due to its binding inside the channel pore more strongly than
carvedilol (Eb −15.4kT) (Figure 16). Both carvedilol and
compound 13 were able to block the loading of GTTR into the
hair cells, further supporting the notion that the protective
effect of both compounds is due to their block of the MET
channel and the prevention of AG uptake into hair cells.
Finally, to exclude a protective effect specific to gentamicin,
we compared the protection of carvedilol and compound 13
against neomycin using hair cells in the lateral line organs of
zebrafish larvae. Both compounds were protective against
neomycin damage at a concentration of ≥12.5 μM, and found
to be slightly less effective when tested against gentamicin,
providing full protection at a concentration ≥ 25 μM. In
addition, neither carvedilol nor compound 13 interfered with
gentamicin antimicrobial activity.
In conclusion, we established that carvedilol is able to
protect cochlear cultures from AG-induced damage, although it
is also cytotoxic in vitro at higher concentrations. We have
established a clear SAR identifying the need for a carbazole
moiety, a basic center, and preferentially an anisole moiety.
The toxicity observed in vitro with cochlear cultures may not
be an issue as carvedilol is widely used in the clinic and is not
associated with hearing loss. Furthermore, carvedilol and its
derivatives did not show a toxic effect in vivo with zebrafish
larvae at 30 μM. Although the “therapeutic window” is narrow
in vitro, our current data show that carvedilol and its
derivatives are a valid chemical starting point for the future
development of drugs that will prevent AGs induced
ototoxicity, and that the MET channel is a potential target
for such compounds.
■ EXPERIMENTAL SECTION
All commercial reagents were purchased from Sigma-Aldrich, Alfa
Aesar, Apollo Scientific, Fluorochem or Tokyo Chemical Industry and
of the highest available purity. Unless otherwise stated, chemicals
were used as supplied without further purification. Anhydrous
solvents were purchased from Acros (AcroSeal) or Sigma-Aldrich
(SureSeal) and were stored under nitrogen. Petroleum ether refers to
the fraction with a boiling point between 40 and 60 °C. Thin-layer
chromatography: precoated aluminum-backed plates (60 F254, 0.2
mm thickness, Merck) were visualized under both short- and long-
wave UV light (254 and 366 nm). Flash column chromatography was
carried out using commercial prepacked columns from Biotage, Isco,
Grace, or filled with Merck silica gel 60 (40−63 μm) or C18 silica on
an ISCO Combiflash Rf or a Biotage Isolera Prime. HPLC
purification was performed on an Agilent 1100 series HPLC
spectrometer, using a Phenomenex Luna 10 μm C18 150 mm × 15
mm column, eluted using water and acetonitrile at 15 mL/min and
detected at 254 nm.
Proton nuclear magnetic resonance spectra were recorded at 500 or
600 MHz on a Varian VNMRS 500 MHz or Varian VNMRS 600
MHz spectrometers, respectively (at 30 °C), using residual isotopic
solvent (CHCl3, δ = 7.27 ppm, DMSO δ = 2.50 ppm) as an internal
reference. Chemical shifts are quoted in parts per million (ppm).
Coupling constants (J) are recorded in hertz (Hz). The following
abbreviations are used in the assignment of NMR signals: s (singlet),
d (doublet), t (triplet), q (quartet), qn (quintet), m (multiplet), bs
(broad singlet), dd (doublet of doublet), and dt (doublet of triplet).
Carbon nuclear magnetic resonance spectra were recorded at 125 or
151 MHz on Varian 500 or 600 MHz spectrometers, respectively, and
are proton-decoupled, using residual isotopic solvent (CHCl3, δ =
77.00 ppm, DMSO δ = 39.52 ppm) as an internal reference.
LCMS data were recorded on a Waters 2695 HPLC using a Waters
2487 UV detector and a Thermo LCQ ESI-MS. Samples were eluted
through a Phenomenex Lunar 3 μm C18 50 mm × 4.6 mm column,
using water and acetonitrile acidified by 0.1% formic acid at 1 mL/
min and detected at 254 nm. The following methods were used:
method 1: water (+0.1% formic acid)/acetonitrile (+0.1% formic
acid) = from 65/35 to 10/90 in 3.5 min, then isocratic 10/90 0.4 min,
then from 10/90 to 65/35 in 0.1 min; method 2: water (+0.1% formic
acid)/acetonitrile (+0.1% formic acid) = from 70/30 to 10/90 in 5
min, then isocratic 10/90 1.0 min, then from 10/90 to 70/30 in 0.5
min, and then isocratic 70/30 for 0.5 min.
LCMS (MDAP): LCMS data were recorded on a Shimatzu
Prominence Series coupled to a LCMS-2020 ESI and APCI mass
spectrometer. Samples were eluted through a Phenomenex Gemini 5μ
C18 110A 250 mm × 4.6 mm column, using water and acetonitrile
acidified by 0.1% formic acid at 1 mL/min and detected at 254 nm.
The following method, marked as method 3, was used: water (+0.1%
formic acid)/acetonitrile (+0.1% formic acid) = isocratic 95/5 1 min,
then from 95/5 to 5/95 in 20 min, then isocratic 5/95 for 4 min, and
then from 5/95 to 70/30 in 5 min.
Physicochemical properties were calculated using MarvinSketch
16.8.15.0 by ChemAxon (https://www.chemaxon.com).
Compound purity was assured by a combination of high-field
multinuclear NMR (H, C) and HPLC; purity by the later was always
>95%.
Chemistry. Synthesis of 2-((2-Methoxyphenoxy)methyl)oxirane
(1). A mixture of 2-methoxyphenol (1.0 g, 8.06 mmol), 2-
(bromomethyl)oxirane (0.69 mL, 8.06 mmol), and anhydrous
K2CO3 (2.23 g, 16.11 mmol) in dimethylformamide (DMF, 5 mL)
was stirred at 70 °C for 6 h. After cooling, the solvent was evaporated
under reduced pressure, the residue was dissolved in water, and the
aqueous phase was extracted with ethyl acetate. The organic phase
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was washed with saturated NaHCO3 solution, dried over MgSO4,
filtered, and concentrated. The residue was then purified by flash
column chromatography gradient elution of petroleum ether/ethyl
acetate (100/0 to 0/100) to give 1 as an oil which crystallized to give
a colorless solid (0.90 g, 62%). 1H NMR (DMSO 600 MHz): δ 6.95
(td, J = 7.6, 1.6 Hz, 2H), 6.90 (td, J = 7.7, 1.6 Hz, 1H), 6.85 (td, J =
7.6, 1.6 Hz, 1H), 4.25 (dd, J = 11.3, 2.8 Hz, 1H), 3.78 (dd, J = 11.3,
6.6 Hz, 1H), 3.74 (s, 3H), 3.30 (d, J = 2.6 Hz, 1H), 2.81 (dd, J = 5.1,
4.2 Hz, 1H), 2.67 (dd, J = 5.1, 2.7 Hz, 1H).
Synthesis of 1-(2-Methoxyphenoxy)-3-[2-(2-methoxyphenoxy)-
ethylamino]propan-2-ol (2). A solution of 2-(2-methoxyphenoxy)-
ethanamine (0.84 mL, 5.55 mmol) in ethylene glycol dimethyl ether
(1 mL) was heated to 80 °C. Then, a solution of 1 (0.25 g, 1.39
mmol) in ethylene glycol dimethyl ether (1 mL) was added dropwise,
and the reaction mixture was stirred at 80 °C for 5 h. Then, 1 (0.12 g,
0.67 mmol) in ethylene glycol dimethyl ether (0.50 mL) was added
dropwise, and the reaction mixture was stirred at 80 °C for further 1
h. After cooling, the solvent was evaporated under reduced pressure,
and the residue was purified by flash column chromatography gradient
elution of petroleum ether/ethyl acetate (100/0 to 0/100). The
compound was further purified by HPLC gradient elution of water/
acetonitrile = 95:5 to 0:100 in 20 min to give 2 as a colorless solid
(0.12 g, 25%). 1H NMR (DMSO 500 MHz): δ 6.96−6.94 (m, 4H),
6.89−6.85 (m, 4H), 4.95 (s, 1H), 3.99 (t, J = 5.6 Hz, 2H), 3.93−3.83
(m, 3H), 3.73 (d, J = 3.2 Hz, 6H), 2.88 (t, J = 5.6 Hz, 2H), 2.80−2.71
(m, 1H), 2.68−2.60 (m, 1H). 13C NMR (DMSO 126 MHz): δ
149.78, 149.71, 148.83, 148.66, 121.55, 121.45, 121.25, 121.23,
114.40, 114.26, 113.01, 112.93, 72.13, 69.08, 68.78, 56.07, 53.03,
48.98. LCMS: method 2: RT: 0.71 min; M + H+: 348.38. LCMS:
method 3, RT = 11.22 min; M + H+: 348.40.
Synthesis of 1-(2-Bromoethoxy)-2-methoxy-benzene (3). A
solution of 2-methoxyphenol (4.0 mL, 36.38 mmol) and NaOH
(4.37 g, 109.13 mmol) in water (25 mL) was added dropwise to 1,2-
dibromoethane (25.08 mL, 291.03 mmol), and the reaction mixture
was then stirred at reflux for 3 h. After cooling, the phases were
separated, and the organic phase was concentrated. The residue was
purified by flash column chromatography gradient elution of
petroleum ether/ethyl acetate (100/0 to 50/50) to give a yellow oil
which crystallized at room temperature to give 3 as a yellow solid
(1.84 g, 22%). 1H NMR (DMSO 500 MHz): δ 7.00−6.95 (m, 2H),
6.95−6.91 (m, 1H), 6.89−6.84 (m, 1H), 4.27 (t, J = 5.5 Hz, 2H),
3.80−3.73 (m, 5H).
Synthesis of 2-(2-Methoxyphenoxy)-N-[2-(2-methoxyphenoxy)-
ethyl]ethanamine (4). 2-(2-Methoxyphenoxy)ethanamine (0.90 mL,
5.98 mmol) and tryethylamine (TEA, 1.67 mL, 11.96 mmol) were
added to a solution of 3 (1.38 g, 5.98 mmol) in tetrahydrofuran
(THF, 10 mL), and the reaction mixture was stirred at 65 °C for 5 h.
Then, TEA (0.83 mL, 5.98 mmol) was added, and the reaction
mixture was stirred at 65 °C for further 1 h. After cooling, the solvent
was removed under reduced pressure, and the residue was triturated
with water and ethyl acetate. The precipitate was filtered to give a first
crop of the desired compound as a colorless solid (0.52 g, 26%). The
layers were then separated, and the aqueous phase was extracted with
ethyl acetate. The combined organic phase was washed with brine,
dried over MgSO4, filtered, and concentrated to give 4 as a yellow oil
which crystallized at room temperature. The solid was washed four
times with a mixture of water/ethyl acetate (5/1) to give a second
crop of the desired compound 4 as an off-white solid (0.28 g, 14%).
1H NMR (DMSO 600 MHz): δ 6.96−6.93 (m, 4H), 6.89−6.82 (m,
4H), 4.00 (t, J = 5.6 Hz, 4H), 3.72 (s, 6H), 2.93 (t, J = 5.6 Hz, 4H).
13C NMR (DMSO 151 MHz): δ 149.64, 148.49, 121.52, 121.16,
114.16, 112.66, 68.93, 55.88, 48.67. LCMS: method 2: RT: 0.68 min;
M + H+: 318.12. LCMS: method 3, RT = 11.37; M + H+: 318.35.
Synthesis of 4-(Oxiran-2-ylmethoxy)-9H-carbazole (5). To a
solution of NaOH (0.48 g, 12.01 mmol) in water (10 mL), 9H-
carbazol-4-ol (2.0 g, 10.92 mmol) and DMSO (5 mL) were added
followed by dropwise addition of 2-(bromomethyl)oxirane (1.4 mL,
16.37 mmol). The reaction mixture was then heated at 45 °C for 16 h.
After cooling, water (20 mL) was added, and the reaction mixture was
stirred at room temperature for 1 h. The precipitate formed was
filtered, and the wet solid was recrystallized from isopropanol to give
5 as a brown solid (0.82 g, 31%). A second crop of 5 was also
obtained as a brown solid (0.63 g, 24%). 1H NMR (DMSO 600
MHz): δ 11.26 (s, 1H), 8.15 (d, J = 7.8 Hz, 1H), 7.44 (d, J = 8.0 Hz,
1H), 7.33 (dt, J = 8.2, 7.1 Hz, 1H), 7.28 (t, J = 8.0 Hz, 1H), 7.17−
7.11 (m, 1H), 7.08 (d, J = 8.0 Hz, 1H), 6.68 (d, J = 7.9 Hz, 1H), 4.54
(dd, J = 11.2, 2.6 Hz, 1H), 4.08 (dd, J = 11.2, 6.2 Hz, 1H), 3.52 (ddd,
J = 6.5, 4.4, 2.5 Hz, 1H), 2.92 (t, J = 4.7 Hz, 1H), 2.83 (dd, J = 5.1,
2.7 Hz, 1H). 13C NMR (DMSO 151 MHz): δ 154.93, 141.56, 139.39,
126.89, 125.10, 122.72, 122.00, 119.09, 111.93, 110.91, 104.68,
101.14, 69.21, 50.38, 44.26. LCMS: method 2: RT: 3.65 min; M +
H+: 240.16.
Synthesis of 1-(9H-Carbazol-4-yloxy)-3-(2-phenoxyethylamino)-
propan-2-ol (6). A solution of 2-phenoxyethanamine (0.22 mL, 1.67
mmol) in ethylene glycol dimethyl ether (0.75 mL) was heated at 80
°C, and then a solution of 5 (0.10 g, 0.42 mmol) in ethylene glycol
dimethyl ether (0.75 mL) was added dropwise, and the reaction
mixture was stirred at 80 °C for 24 h. After cooling, the solvent was
removed under reduced pressure, and the residue was purified by flash
column chromatography gradient elution of petroleum ether/ethyl
acetate (100/0 to 0/100) to give the desired compound which was
further purified by reverse phase HPLC gradient elution of water/
acetonitrile = 95:5 to 0:100 in 20 min to give 6 as an off-white solid
(0.085 g, 54%). 1H NMR (DMSO 600 MHz): δ 11.21 (s, 1H), 8.20
(d, J = 7.8 Hz, 1H), 7.42 (d, J = 8.0 Hz, 1H), 7.34−7.28 (m, 1H),
7.28−7.21 (m, 3H), 7.10 (t, J = 7.4 Hz, 1H), 7.05 (d, J = 8.0 Hz, 1H),
6.89 (dd, J = 7.9, 6.3 Hz, 3H), 6.66 (d, J = 7.9 Hz, 1H), 5.13 (d, J =
4.9 Hz, 1H), 4.19−4.11 (m, 2H), 4.11−4.06 (m, 1H), 4.01 (t, J = 5.6,
2H), 2.93 (td, J = 5.5, 2H), 2.81 (dd, J = 11.9, 6.8 Hz, 1H), 2.01 (s,
1H). 13C NMR (DMSO 151 MHz): δ 159.02, 155.40, 141.53, 139.34,
129.88, 126.92, 124.94, 122.90, 122.17, 119.00, 114.86, 112.00,
110.77, 104.25, 100.87, 70.89, 68.91, 67.86, 53.08, 48.90. LCMS:
method 2: RT: 1.53 min; M + H+: 377.19.
Synthesis of 1-(Butylamino)-3-(9H-carbazol-4-yloxy)propan-2-ol
(7). A solution of butan-1-amine (0.50 mL, 5.02 mmol) in ethylene
glycol dimethyl ether (0.75 mL) was heated at 80 °C in a sealed tube.
Then, a solution of 5 (0.12 g, 0.50 mmol) in ethylene glycol dimethyl
ether (0.75 mL) was added dropwise, and the reaction mixture was
stirred at 80 °C for 2.5 h. After cooling, the solvent was removed
under reduced pressure, and the residue was left overnight, continuing
the reaction with no solvent. The residue was then purified by flash
column chromatography gradient elution of petroleum ether/ethyl
acetate (100/0 to 0/100) to give the desired compound as a yellow
gum, which was further purified by reverse phase HPLC gradient
elution of water/acetonitrile = 95/5 to 0/100 in 20 min to give 7 as a
pale yellow solid (0.055 g, 35%). 1H NMR (DMSO 500 MHz): δ
11.21 (s, 1H), 8.21 (d, J = 7.7 Hz, 1H), 7.43 (d, J = 8.0 Hz, 1H),
7.35−7.30 (m, 1H), 7.28 (t, J = 8.0 Hz, 1H), 7.12 (t, J = 7.4 Hz, 1H),
7.06 (d, J = 8.0 Hz, 1H), 6.67 (d, J = 7.9 Hz, 1H), 5.04 (br s, 1H),
4.18−4.11 (m, 2H), 4.09−4.04 (m, 1H), 2.83 (dd, J = 11.9, 4.8 Hz,
1H), 2.73 (dd, J = 11.9, 6.8 Hz, 1H), 2.55 (dt, J = 6.9, 2.8 Hz, 2H),
1.47−1.35 (m, 2H), 1.35−1.25 (m, 2H), 0.85 (t, J = 7.3 Hz, 3H). 13C
NMR (DMSO 126 MHz): δ 155.47, 141.59, 139.40, 126.90, 124.94,
122.90, 122.23, 118.94, 110.78, 109.99, 104.25, 100.95, 71.05, 68.84,
53.19, 49.61, 32.28, 20.39, 14.36. LCMS: method 2: RT: 0.69 min; M
+ H+: 313.02. LCMS: method 3, RT = 11.65; M + H+: 313.35.
Synthesis of 1-(9H-Carbazol-4-yloxy)-3-(4-phenylpiperazin-1-yl)-
propan-2-ol (8). A mixture of 5 (0.20 g, 0.84 mmol) and phenyl
piperazine (0.13 mL, 0.84 mmol) in ethanol (25 mL) was stirred at 65
°C for 16 h. The reaction solvent was then removed under reduced
pressure, and the residue was purified by flash column chromatog-
raphy gradient elution of petroleum ether/ethyl acetate (100/0 to 0/
100) to give 8 as a colorless oil which crystallized on standing (0.28 g,
80%). 1H NMR (CDCl3 500 MHz): δ 8.29 (d, J = 7.8 Hz, 1H), 8.09
(s, 1H), 7.44−7.37 (m, 1H), 7.37−7.21 (m, 5H), 7.06 (d, J = 8.1 Hz,
1H), 6.95 (d, J = 8.1, 2H), 6.88 (t, J = 7.3 Hz, 1H), 6.69 (d, J = 8.0
Hz, 1H), 4.42−4.29 (m, 2H), 4.28−4.23 (m, 1H), 3.32−3.19 (m,
5H), 2.95−2.87 (m, 1H), 2.87−2.75 (m, 2H), 2.73−2.65 (m, 2H).
13C NMR (CDCl3 126 MHz): δ 151.17, 150.82, 144.11, 138.69,
129.13, 126.66, 125.01, 122.93, 119.88, 119.67, 117.73, 116.15,
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.8b01325
J. Med. Chem. 2019, 62, 5312−5329
5324
110.01, 103.82, 101.21, 70.28, 65.85, 61.07, 53.46, 53.31, 49.30.
LCMS: method 3, RT = 12.39; M + H+: 402.25.
Synthesis of 1-[Bis[2-(2-methoxyphenoxy)ethyl]amino]-3-(9H-
carbazol-4-yloxy)propan-2-ol (9). A solution of 4 (0.13 g, 0.42
mmol) in ethylene glycol dimethyl ether (0.50 mL) was heated in a
sealed tube at 80 °C. A solution of 5 (0.10 g, 0.42 mmol) in ethylene
glycol dimethyl ether (0.50 mL) was added dropwise, and the reaction
was heated at 80 °C for 5 h. Then, 4 (0.13 g, 0.42 mmol) was added,
and the reaction mixture was stirred at 80 °C for 24 h. Then, a
solution of 4 (0.07 g, 0.21 mmol) in ethylene glycol dimethyl ether
(0.50 mL) was added, and the reaction mixture was stirred at 80 °C
for further 18 h. After cooling, the solvent was removed under
reduced pressure, and the residue was purified by flash column
chromatography gradient elution of petroleum ether/ethyl acetate
(100/0 to 0/100) to give the desired compound which was further
purified by flash column chromatography gradient elution of
petroleum ether/ethyl acetate (100/0 to 20/100) to give the desired
compound as a yellow oil which was triturated with methanol/
acetone to give 9 as a colorless solid (0.12 g, 52%). 1H NMR (DMSO
600 MHz): δ 11.20 (s, 1H), 8.22 (d, J = 7.7 Hz, 1H), 7.40 (d, J = 8.1
Hz, 1H), 7.31−7.25 (m, 1H), 7.22 (t, J = 8.0 Hz, 1H), 7.09−7.00 (m,
2H), 6.88 (d, J = 8.0 Hz, 2H), 6.84−6.80 (m, 2H), 6.75−6.69 (m,
4H), 6.58 (d, J = 7.9 Hz, 1H), 4.92 (d, J = 4.6 Hz, 1H), 4.23−4.15
(m, 2H), 4.14−4.07 (m, 1H), 4.00−3.95 (m, 4H), 3.65 (s, 6H),
3.05−2.96 (m, 5H), 2.83 (dd, J = 13.3, 6.0 Hz, 1H). 13C NMR
(DMSO 151 MHz): δ 155.47, 149.41, 148.45, 141.53, 139.33, 126.91,
124.88, 122.90, 122.22, 121.17, 121.07, 118.96, 113.45, 112.58,
111.99, 110.73, 104.13, 100.65, 70.37, 68.42, 67.42, 58.54, 55.86,
54.74. LCMS: method 2: RT: 2.37 min; M + H+: 557.40. LCMS:
method 3, RT = 14.04 min; M + H+: 557.60.
Synthesis of 4-(3-Bromopropoxy)-9H-carbazole (10). A solution
of 4-hydroxycarbazole (0.50 g, 2.73 mmol), 1,3-dibromopropane
(0.83 mL, 8.19 mmol), and KOH (0.15 g, 2.73 mmol) in acetonitrile
(25 mL) was stirred at room temperature overnight. After this period,
1,3-dibromopropane (0.42 mL, 4.09 mmol) and KOH (0.046 g, 0.82
mmol) were added, and the stirring was continued for further 3 h.
The solvent was then removed under reduced pressure, and the
residue was purified by flash column chromatography gradient elution
of petroleum ether/ethyl acetate (100/0 to 50/50) to give 10 as a
colourless solid (0.50 g, 59%). 1H NMR (CDCl3 500 MHz): δ 8.25
(d, J = 7.8 Hz, 1H), 8.07 (s, 1H), 7.46−7.37 (m, 2H), 7.36−7.30 (m,
1H), 7.26−7.22 (m, 1H), 7.07 (d, J = 8.1 Hz, 1H), 6.71 (d, J = 8.0
Hz, 1H), 4.41 (t, J = 5.8 Hz, 2H), 3.78 (t, J = 6.5 Hz, 2H), 2.55 (p, J =
6.2 Hz, 2H). LCMS: method 1: RT: 3.67 min; M + H+: 304.06,
306.05.
Synthesis of 4-(4-Bromobutoxy)-9H-carbazole (11). A mixture of
4-hydroxycarbazole (0.50 g, 2.73 mmol), 1,4-dibromobutane (0.89
mL, 8.19 mmol), and KOH (0.15 g, 2.73 mmol) in acetonitrile (25
mL) was stirred at room temperature for 16 h. The solvent was
removed under reduced pressure, and the residue was purified by flash
column chromatography gradient elution of petroleum ether/ethyl
acetate (100/0 to 50/50) to give 11 as a colorless solid (0.47 g, 52%).
1H NMR (CDCl3 500 MHz): δ 8.28 (d, J = 7.8 Hz, 1H), 8.05 (s,
1H), 7.43−7.36 (m, 2H), 7.32 (t, J = 8.0 Hz, 1H), 7.27−7.22 (m,
1H), 7.04 (d, J = 8.1 Hz, 1H), 6.66 (d, J = 8.0 Hz, 1H), 4.27 (t, J = 5.8
Hz, 2H), 3.58 (t, J = 6.4 Hz, 2H), 2.27−2.21 (m, 2H), 2.20−2.13 (m,
2H). 13C NMR (CDCl3 126 MHz): δ 138.65, 137.28, 126.65, 124.93,
122.93, 119.65, 117.73, 109.94, 103.49, 100.97, 88.29, 88.28, 66.76,
33.64, 29.61, 28.00. LCMS: method 1: RT: 3.84 min; M + H+:
318.03, 319.95.
Synthesis of 4-(6-Bromohexoxy)-9H-carbazole (12). A solution of
4-hydroxy carbazole (0.50 g, 2.73 mmol), 1,6-dibromohexane (1.26
mL, 8.19 mmol), and KOH (0.31 g, 5.46 mmol) in acetonitrile (25
mL) was stirred at room temperature for 5 h. Then, the solvent was
removed under reduced pressure, and the residue was purified by flash
column chromatography gradient elution of petroleum ether/ethyl
acetate (100:0 to 0:100) to give 12 as a pale yellow solid (0.48 g,
51%). 1H NMR (DMSO 600 MHz): 11.21 (s, 1H), 8.13 (dd, J = 7.8,
1.2 Hz, 1H), 7.43 (dt, J = 8.2, 0.9 Hz, 1H), 7.31 (ddd, J = 8.1, 7.1, 1.2
Hz, 1H), 7.26 (t, J = 8.0 Hz, 1H), 7.13 (ddd, J = 7.9, 7.2, 1.0 Hz, 1H),
7.04 (d, J = 8.0 Hz, 1H), 6.65 (d, J = 7.9 Hz, 1H), 4.17 (t, J = 6.3 Hz,
2H), 3.53 (t, J = 6.7 Hz, 2H), 1.91−1.82 (m, 4H), 1.63−1.45 (m,
4H). LCMS: method 2: RT: 6.00 min; M + H+: 346.10, 348.06.
Another fraction was isolated to give the bis-alkylated product as a
yellow solid (0.20 g, 14%).
Synthesis of 3-(9H-Carbazol-4-yloxy)-N-[2-(2-methoxyphenoxy)-
ethyl]propan-1-amine (13). A solution of 10 (0.10 g, 0.33 mmol), 2-
(2-methoxyphenoxy)ethanamine (0.15 mL, 0.99 mmol), and
anhydrous K2CO3 (0.14 g, 0.99 mmol) in anhydrous DMF (5 mL)
was stirred at room temperature under a nitrogen atmosphere
overnight. The solvent was then removed under reduced pressure, and
the residue was dissolved in DCM. The organic phase was washed
with water (five times), dried over MgSO4, filtered, and concentrated.
The residue was purified by flash column chromatography gradient
elution of petroleum ether/ethyl acetate (100/0 to 0/100). The
compound obtained was then further purified by HPLC gradient
elution of water/acetonitrile = 95/5 to 0/100 in 20 min to give 13 as
an off-white solid (0.025 g, 19%). 1H NMR (DMSO 600 MHz): δ
11.21 (s, 1H), 8.13 (d, J = 7.8 Hz, 1H), 7.42 (d, J = 8.0 Hz, 1H), 7.30
(ddd, J = 8.2, 7.1, 1.2 Hz, 1H), 7.26 (t, J = 8.0 Hz, 1H), 7.14−7.07
(m, 1H), 7.04 (d, J = 8.0 Hz, 1H), 6.93−6.90 (m, 2H), 6.86 (td, J =
7.7, 1.7 Hz, 1H), 6.82 (td, J = 7.6, 1.6 Hz, 1H), 6.67 (d, J = 7.9 Hz,
1H), 4.25 (t, J = 6.1 Hz, 2H), 3.98 (t, J = 5.8 Hz, 2H), 3.70 (s, 3H),
2.93−2.82 (m, 4H), 2.04 (p, J = 6.5 Hz, 2H). 13C NMR (DMSO 151
MHz): δ 155.44, 149.64, 148.51, 141.51, 139.34, 126.94, 124.91,
122.56, 122.20, 121.46, 121.15, 119.03, 114.15, 112.66, 111.89,
110.83, 104.15, 100.85, 68.83, 66.14, 55.88, 48.77, 46.61, 30.04.
LCMS: method 2: RT: 1.77 min; M + H+: 391.25; LCMS: method 3,
RT = 12.64; M + H+: 391.45.
Synthesis of 4-(9H-Carbazol-4-yloxy)-N-[2-(2-methoxyphenoxy)-
ethyl]butan-1-amine (14). To a solution of 11 (0.25 g, 0.79 mmol)
in THF (20 mL) were added TEA (0.24 mL, 1.74 mmol) and 2-(2-
methoxyphenoxy)ethanamine (0.13 g, 0.79 mmol), and the reaction
was stirred at 65 °C for 4 h. The reaction mixture was cooled to room
temperature and 2-(2-methoxyphenoxy)ethanamine (0.13 g, 0.79
mmol) and TEA (0.16 mL, 1.18 mmol) were added. The reaction
mixture was reheated to 65 °C and stirred for further 20 h. After
cooling, the solvent was removed under reduced pressure, and the
residue was purified by flash column chromatography gradient elution
of petroleum ether/ethyl acetate (100/0 to 0/100) to give 14 as a
colorless oil (0.11 g, 32%). 1H NMR (CDCl3 500 MHz): δ 8.31 (d, J
= 7.6 Hz, 2H), 7.41−7.33 (m, 2H), 7.31 (t, J = 8.0 Hz, 1H), 7.25−
7.20 (m, 1H), 7.02 (d, J = 8.1 Hz, 1H), 6.97−6.86 (m, 4H), 6.64 (d, J
= 8.0 Hz, 1H), 4.21 (t, J = 6.5 Hz, 2H), 4.14 (t, J = 5.2 Hz, 2H), 3.84
(s, 3H), 3.05 (t, J = 5.3 Hz, 2H), 2.76 (t, J = 7.3 Hz, 2H), 2.10−1.92
(m, 2H), 1.83−1.72 (m, 3H). 13C NMR (CDCl3 126 MHz): δ
155.60, 140.94, 138.70, 126.63, 124.82, 123.03, 122.72, 121.47,
120.90, 119.54, 114.01, 112.61, 111.79, 109.98, 109.89, 103.31,
100.95, 88.27, 68.77, 67.74, 55.78, 49.56, 48.83, 27.31, 26.82. LCMS:
method 3, RT = 12.74; M + H+: 405.20.
Synthesis of 4-[6-(2-Methoxyphenoxy)hexoxy]-9H-carbazole
(15). A solution of 12 (0.10 g, 0.29 mmol), 2-methoxyphenol (0.06
mL, 0.58 mmol), and KOH (0.03 g, 0.58 mmol) in acetonitrile (8
mL) was stirred at room temperature for 6 h. Then, 2-methoxyphenol
(0.06 mL, 0.58 mmol) and KOH (0.03 g, 0.58 mmol) were added,
and the stirring continued for further 60 h. After this period, the
solvent was removed under reduced pressure, and the residue was
purified by flash column chromatography gradient elution of
petroleum ether/ethyl acetate (100:0 to 60:40) to give the desired
compound which was washed with methanol to give 15 as an off-
white solid (0.045 g, 40%). 1H NMR (DMSO 600 MHz): δ 11.21 (s,
1H), 8.12 (d, J = 7.8 Hz, 1H), 7.42 (d, J = 8.0 Hz, 1H), 7.32−7.28
(m, 1H), 7.26 (t, J = 8.0 Hz, 1H), 7.09 (t, J = 7.5 Hz, 1H), 7.04 (d, J
= 8.0 Hz, 1H), 6.91 (td, J = 7.7, 1.8 Hz, 2H), 6.87−6.80 (m, 2H),
6.66 (d, J = 7.9 Hz, 1H), 4.19 (t, J = 6.3 Hz, 2H), 3.94 (t, J = 6.5 Hz,
2H), 3.71 (s, 3H), 1.92 (p, J = 6.6 Hz, 2H), 1.76 (p, J = 6.8 Hz, 2H),
1.63 (p, J = 7.5 Hz, 2H), 1.55 (q, J = 7.8 Hz, 2H). 13C NMR (DMSO
600 MHz): δ 155.45, 149.54, 148.66, 141.52, 139.34, 126.94, 124.91,
122.52, 122.20, 121.20, 121.16, 119.03, 113.74, 112.69, 111.89,
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110.83, 104.15, 100.84, 68.53, 67.71, 55.92, 40.24, 29.30, 29.22, 25.94,
25.74. LCMS: method 2: RT: 5.96 min; M + H+: 390.10.
Synthes is of 3- (9H-Carbazol-4-y loxy)-N,N-bis [2- (2-
methoxyphenoxy)ethyl]propan-1-amine (16). A solution of 4
(0.32 g, 0.97 mmol), 10 (0.10 g, 0.32 mmol), and K2CO3 (0.13 g,
0.97 mmol) in anhydrous DMF (5 mL) was stirred at room
temperature under a nitrogen atmosphere for 36 h. The solvent was
then removed under reduced pressure, and the residue was purified by
three sequential flash column chromatography: first column, gradient
elution of DCM/methanol = 90/10; second column, gradient elution
of DCM/methanol = (100/0 to 99/1); and third column, gradient
elution of petroleum ether/ethyl acetate (100/0 to 0/100) to give 16
as a colorless solid (4.8 mg, 3%). 1H NMR (CDCl3 500 MHz): δ 8.29
(d, J = 7.8 Hz, 1H), 8.07 (s, 1H), 7.47−7.33 (m, 2H), 7.30 (t, J = 8.0
Hz, 1H), 7.18 (t, J = 7.4 Hz, 1H), 7.03 (d, J = 8.1 Hz, 1H), 6.92−6.83
(m, 5H), 6.83−6.73 (m, 4H), 6.65 (d, J = 8.0 Hz, 1H), 4.32 (t, J = 6.0
Hz, 2H), 4.16−4.09 (m, 4H), 3.80 (s, 5H), 3.12 (t, J = 6.4 Hz, 4H),
3.03 (t, J = 6.9 Hz, 2H), 2.20 (p, J = 6.5 Hz, 2H). 13C NMR (CDCl3
126 MHz): δ 159.00, 155.63, 151.71, 146.04, 136.37, 129.83, 126.69,
124.81, 122.91, 120.96, 120.82, 119.65, 113.17, 111.74, 109.98,
109.86, 103.25, 100.88, 67.43, 65.68, 55.81, 53.88. LCMS: method 3,
RT = 14.01; M + H+: 541.30.
Synthesis of Ethyl 2-(9H-Carbazol-4-yloxy)acetate (17). A
mixture of 4-hydroxycarbazole (1.90 g, 10.38 mmol), ethyl
chloroacetate (1.11 mL, 10.38 mmol), and K2CO3 (1.43 g, 10.38
mmol) in acetone (150 mL) was stirred at 56 °C for 16 h. The solvent
was removed under reduced pressure, and the residue was used in the
next step with no further purification.
Synthesis of 2-(9H-Carbazol-4-yloxy)acetic Acid (18). A solution
of 17 (0.72 g, 2.67 mmol) in THF (25 mL) was stirred with 1 M
aqueous NaOH (20 mL, 20 mmol) at room temperature for 16 h.
The reaction mixture was then acidified with 1 M HCl, and the
organic layer was separated and concentrated under reduced pressure.
The residue was triturated with ethyl acetate to give 18 as a colorless
solid (0.16 g, 23%) and used in the next step with no further
purification. 1H NMR (DMSO 500 MHz): δ 11.27 (s, 1H), 8.24 (d, J
= 7.8 Hz, 1H), 7.43 (d, J = 8.1 Hz, 1H), 7.32 (t, J = 7.6 Hz, 1H), 7.26
(t, J = 8.0 Hz, 1H), 7.13 (t, J = 7.5 Hz, 1H), 7.07 (d, J = 8.0 Hz, 1H),
6.57 (d, J = 8.0 Hz, 1H), 4.87 (s, 2H). LCMS: method 2: RT: 0.52
min; M + H+: 242.03.
Synthesis of 2-(9H-Carbazol-4-yloxy)-N-[2-(2-methoxyphenoxy)-
ethyl]acetamide (19). To a solution of 18 (0.075 g, 0.29 mmol), 2-
(2-methoxyphenoxy)ethanamine (0.05 g, 0.29 mmol) and HOBt
(0.054 g, 0.35 mmol) in anhydrous DMF (2 mL), EDC hydrochloride
(0.068 g, 0.35 mmol), and DIPEA (0.15 mL, 0.88 mmol) were added,
and the reaction was stirred at room temperature for 16 h. After this
period, the solvent was removed under reduced pressure, and the
residue was purified by flash column chromatography gradient elution
of petroleum ether/ethyl acetate (90/10 to 0/100) to give 19 as a
colorless solid (0.08 g, 64%). 1H NMR (CDCl3 500 MHz): δ 8.22 (d,
J = 7.8 Hz, 1H), 8.17 (br s, 1H), 7.51−7.38 (m, 2H), 7.34 (d, J = 7.5
Hz, 1H), 7.29 (t, J = 8.0 Hz, 1H), 7.10 (d, J = 8.1 Hz, 1H), 7.00 (t, J =
7.5 Hz, 1H), 6.97−6.92 (m, 1H), 6.91−6.84 (m, 1H), 6.78 (d, J = 7.9
Hz, 1H), 6.63 (d, J = 8.0 Hz, 1H), 4.81 (s, 2H), 4.15 (t, J = 5.1 Hz,
2H), 3.81 (q, J = 5.4 Hz, 2H), 3.50 (s, 3H). 13C NMR (CDCl3 126
MHz): δ 168.85, 153.62, 141.03, 138.72, 131.74, 126.68, 125.27,
122.77, 122.32, 120.82, 119.88, 115.40, 111.89, 110.10, 104.89,
101.76, 68.64, 67.85, 55.42, 38.75. LCMS: method 3, RT = 19.52; M
+ H+: 391.20.
Synthesis of 2-(Oxiran-2-ylmethoxy)-9H-carbazole (20). To a
solution of 2-hydroxycarbazole (1.0 g, 5.46 mmol), NaOH (0.24 g,
6.0 mmol) in water (5 mL), a solution of 2-(bromomethyl)oxirane
(0.70 mL, 8.19 mmol) in DMSO (1 mL) was added dropwise. The
reaction mixture was stirred at 45 °C for 16 h. After cooling to room
temperature, the resulting precipitate was filtered and triturated with
isopropanol to give the desired compound 20 as a colorless solid
(0.13 g, 9%). 1H NMR (CDCl3 500 MHz): δ 8.02−7.90 (m, 3H),
7.41−7.31 (m, 2H), 7.21 (t, J = 7.4 Hz, 1H), 6.94 (s, 1H), 6.87 (d, J =
8.5 Hz, 1H), 4.31 (dd, J = 10.9, 3.1 Hz, 1H), 4.06 (dd, J = 10.9, 5.7
Hz, 1H), 3.42 (br s, 1H), 2.94 (t, J = 4.6 Hz, 1H), 2.86−2.76 (m,
1H). LCMS: method 1: RT: 0.60 min; M + H+: 240.02.
Synthesis of 1-(9H-Carbazol-2-yloxy)-3-[2-(2-methoxyphenoxy)-
ethylamino]propan-2-ol (21). A mixture of 20 (0.13 g, 0.56 mmol)
and 2-(2-methoxyphenoxy)ethanamine (0.095 g, 0.56 mmol) in
ethanol (15 mL) was stirred at 65 °C for 16 h. The solvent was
removed under reduced pressure, and the residue was purified by flash
column chromatography gradient elution of DCM/methanol (100/0
to 95/5). The compound obtained was further purified by flash
column chromatography gradient elution of DCM/methanol = (100/
0 to 90/20) to give 21 as a colorless solid (0.076 g, 33%). 1H NMR
(DMSO 600 MHz): δ 11.08 (s, 1H), 7.96 (d, J = 7.7 Hz, 1H), 7.93
(d, J = 8.5 Hz, 1H), 7.40 (d, J = 8.0 Hz, 1H), 7.29−7.23 (m, 1H),
7.11−7.06 (m, 1H), 6.97−6.92 (m, 3H), 6.89−6.82 (m, 2H), 6.76
(dd, J = 8.5, 2.2 Hz, 1H), 5.14−5.03 (m, 1H), 4.03−3.98 (m, 3H),
3.97−3.95 (m, 2H), 3.72 (s, 3H), 2.90 (t, J = 5.6 Hz, 2H), 2.79 (dd, J
= 11.9, 3.9 Hz, 1H), 2.69 (dd, J = 11.8, 6.4 Hz, 1H); 13C NMR
(DMSO 151 MHz): δ 158.31, 149.59, 148.50, 141.48, 140.16, 124.56,
123.09, 121.47, 121.32, 121.16, 119.69, 118.96, 116.62, 114.01,
112.61, 111.04, 108.55, 95.63, 71.39, 68.77, 55.89, 52.93, 48.94;
LCMS: method 3, RT = 12.59; M + H+: 407.15.
Synthesis of 9-(Oxiran-2-ylmethyl)carbazole (22). KOH (0.20 g,
3.59 mmol) was added to a solution of 9H-carbazole (0.50 g, 2.99
mmol) in acetonitrile (5 mL), and the reaction mixture was stirred at
room temperature for 1 h. Then, the reaction mixture was cooled in
an ice bath, and 2-(bromomethyl)oxirane (0.64 mL, 7.48 mmol) was
added dropwise. After the addition, the ice bath was removed, and the
reaction mixture was stirred at room temperature for 20 h. After this
period, the reaction mixture was partitioned between ethyl acetate and
water, and the organic layer was washed with water and brine, dried
over MgSO4, filtered, and concentrated. The residue was triturated
with hexane and recrystallized from ethyl acetate/hexanes to yield 22
as a colorless solid (0.48 g, 68%) and used in the next step with no
further purification. 1H NMR (CDCl3 500 MHz): δ 8.11 (dt, J = 7.8,
1.0 Hz, 2H), 7.53−7.45 (m, 4H), 7.31−7.24 (m, 2H), 7.27 (s, 2H),
4.64 (dd, J = 15.9, 3.4 Hz, 1H), 4.42 (dd, J = 15.9, 4.8 Hz, 1H), 3.38−
3.35 (m, 1H), 2.82 (t, J = 4.4 Hz, 1H), 2.59 (dd, J = 4.8, 2.5 Hz, 1H);
LCMS: method 2, RT = 3.03 min; M + H+: 224.15.
Synthesis of 1-Carbazol-9-yl-3-(2-phenylethylamino)propan-2-
ol (23). A solution of 22 (0.10 g, 0.43 mmol) and phenethylamine
(0.05 mL, 0.43 mmol) in ethanol (5 mL) was stirred at 65 °C for 16
h. Then, the solvent was removed under reduced pressure, and the
residue was purified by flash column chromatography gradient elution
of petroleum ether/ethyl acetate = (100/0 to 0/100) to give 23 as a
colourless oil (0.07 g, 49%). 1H NMR (DMSO 600 MHz): δ 8.11 (d,
J = 7.6 Hz, 2H), 7.57 (d, J = 8.2 Hz, 2H), 7.40 (t, J = 7.6 Hz, 2H),
7.26 (t, J = 7.5 Hz, 2H), 7.20 (d, J = 7.5 Hz, 2H), 7.16 (t, J = 7.4 Hz,
3H), 5.02 (s, 1H), 4.43 (dd, J = 14.8, 5.3 Hz, 1H), 4.24 (dd, J = 14.8,
6.7 Hz, 1H), 3.97 (p, J = 5.9 Hz, 1H), 2.77−2.66 (m, 4H), 2.60 (dd, J
= 11.8, 4.9 Hz, 1H), 2.54 (dd, J = 11.8, 6.1 Hz, 1H). 13C NMR
(DMSO 151 MHz): δ 141.03, 140.92, 129.07, 128.67, 126.27, 125.93,
122.45, 120.47, 119.05, 110.17, 69.24, 53.46, 51.66, 47.48, 36.47.
LCMS: method 3, RT = 12.76 min; M + H+: 345.15.
Synthesis of N-[2-(2-Methoxyphenoxy)ethyl]-2-morpholino-
ethanamine (24). A mixture of 4-(2-aminoethyl)morpholine (0.28
mL, 2.16 mmol), 3 (0.50 g, 2.16 mmol), and TEA (0.90 mL, 6.49
mmol) in THF (25 mL) was stirred at 65 °C for 4 h. After this time,
the solvent was removed under reduced pressure, and the residue was
purified by reverse phase chromatography gradient elution of water/
methanol = 90/10 to 0/100 to give 24 as a colorless oil (0.055 g, 9%).
1H NMR (DMSO 500 MHz): δ 7.03−6.90 (m, 2H), 6.88−6.82 (m,
2H), 3.96 (t, J = 5.6 Hz, 2H), 3.72 (s, 4H), 3.52 (t, J = 4.6 Hz, 4H),
2.83 (t, J = 5.5 Hz, 2H), 2.63 (t, J = 6.4 Hz, 2H), 2.36−2.29 (m, 6H).
LCMS: method 1: RT: 0.39 min; M + H+: 281.13.
Synthesis of 1-(9H-Carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)-
ethyl-(2-morpholinoethyl)amino]propan-2-ol (25). A mixture of 24
(36.6 mg, 0.13 mmol) and 5 (30.6 mg, 0.13 mmol) in ethanol (15
mL) was stirred at 65 °C for 16 h. Then, the solvent was removed
under reduced pressure, and the residue was purified by flash column
chromatography gradient elution of petroleum ether/ethyl acetate =
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(100/0 to 0/100) to give 25 as a colorless oil (0.022 g, 29%). 1H
NMR (CDCl3 500 MHz): δ 8.28 (d, J = 7.7 Hz, 1H), 8.17 (s, 1H),
7.41−7.32 (m, 2H), 7.30 (t, J = 8.0 Hz, 1H), 7.18−7.15 (m, 1H),
7.02 (d, J = 8.0 Hz, 1H), 6.94−6.75 (m, 4H), 6.68 (d, J = 8.0 Hz,
1H), 4.35−4.28 (m, 1H), 4.23−4.18 (m, 2H), 4.09 (t, J = 5.6 Hz,
2H), 3.82 (s, 3H), 3.69 (t, J = 4.7 Hz, 4H), 3.18−3.03 (m, 3H),
3.00−2.91 (m, 2H), 2.89−2.79 (m, 1H), 2.67−2.39 (m, 6H). 13C
NMR (CDCl3 126 MHz): δ 155.28, 149.38, 148.11, 140.89, 138.70,
126.71, 124.86, 122.89, 122.62, 121.24, 120.83, 119.46, 113.13,
112.64, 111.69, 110.00, 103.58, 101.17, 69.56, 68.68, 67.40, 66.63,
57.56, 56.60, 55.73, 55.63, 53.20, 51.72. LCMS: method 3, RT =
12.76; M + H+: 520.30.
Biology. Animal Husbandry. Tissues obtained from wildtype CD-
1mice (Charles Rivers, UK) of either sex, at postnatal day 2 (P2),
were used for the preparation of the mouse cochlear cultures that
were then used for screening, live imaging with GTTR, and
electrophysiology. Animals were raised according to Home Office
guidelines, and all experiments were performed in accordance with the
Home Office Animals (Scientific Procedures) Act 1986 and with
approval of the Animal Welfare and Ethical Review Board at the
University of Sussex.
Mouse Cochlear Culture Preparation. Cochlear cultures were
prepared from CD-1 mice as previously described by Russell and
Richardson.28 In brief, P2 pups were killed by cervical dislocation and
surface sterilized by three 1 min washes in 80% ethanol. Subsequent
dissections were performed in Hanks buffered salt solution (HBSS;
Thermo Shandon 14025050) buffered with 10 mM Hepes (Sigma
H0887) (HBHBSS). Cochleae were removed from the bony labyrinth
and explanted onto collagen-coated (Corning 354236) coverslips and
immersed in rat cochlear culture media (RCM93% DMEM-F12,
7% fetal bovine serum and 10 μg mL−1 ampicillin), sealed in
Maximow slide assemblies, and left to adhere to the collagen for 24 h
at 37 °C.
Mouse Cochlear Culture Protection Assay. Following 24 h
incubation, coverslips with adherent cochleae were removed from
the Maximow slide assemblies, placed in 35 mm Petri dishes (Greiner
Bio-One 627161) and incubated for 48 h at 37 °C in a 5% CO2
incubator in the presence of 1 mL RCM/DMEM-F12 (1:4)
containing either vehicle (0.5% DMSO), 5 μM gentamicin (Sigma
G3632), 5 μM gentamicin along with selected concentrations of the
potentially protective compounds, or the potential protectants alone.
Initially a dose−response experiment was run for the parent
compound from which subsequent concentrations were selected.
Following 48 h incubation, cultures were washed twice in phosphate-
buffered saline, fixed in 3.7% formaldehyde (Sigma F1635), and
stained with TRITC-phalloidin (Sigma P1951). Cultures were
mounted on glass slides with Vectashield (Vector Laboratories H-
1000) and imaged using a Zeiss Axioplan microscope, captured with a
40× objective (0.75 NA). Each screen was repeated 2−8 times.
Confocal Imaging. Confocal microscopy was used for high-
resolution imaging of the mechanosensory hair bundles in order to
assess any morphological disruption induced by the compounds of
interest.
Slides were imaged on a Leica SP8 confocal microscope using the
561 nm laser (at 3% intensity) and a 100× 1.44 NA oil-immersion
lens. Images were captured at a resolution of 736 × 400 pixels (and a
zoom of ×2.0 with a ×4 line average) using a low detector gain (511)
in order to reduce noise and improve image quality. Z-projections
were created in ImageJ.
Quantification of OHC Survival. For quantification of HC survival,
images from the mid-basal region were analyzed. Numbers of OHCs
in a 300 μm long segment of the cochlea were counted at a position
approximately 20% along the length of the cochlea from the basal end.
The presence of a hair bundle was the criterion used as a marker of
HC survival. Although HCs can survive without a bundle,23,29 the
latter is essential for sound transduction and provides a viable marker
when searching for an otoprotectant. IHCs were not counted because
of the lack of damage to this cell type caused by exposure to 5 μM
gentamicin.
Electrophysiology on Mouse Cochlear Cultures. MET currents
were recorded and analyzed using previously described methods.20 In
brief, OHCs in organotypic cultures prepared from P2 CD-1 mice
were studied, with recordings performed in cultures that had been
maintained for 1−2 days in vitro. MET currents were recorded using
the whole-cell configuration of the patch clamp technique both before
and during compound exposure at membrane potentials ranging from
−164 to +96 mV. Currents were elicited by stimulating the OHC hair
bundles using a fluid jet from a pipette (tip diameter 8−10 μm)
driven by a piezoelectric disc.7,30 Mechanical stimuli (filtered at 1.0
kHz, 8-pole Bessel) were applied as 45 Hz sinusoids with driver
voltage amplitudes of ±40 V. Currents were acquired using pClamp
(Molecular Devices) software and stored on computer for off-line
analysis. For all recordings, series resistance compensation was applied
(60−80%), and the average residual series resistance was calculated to
be 1.37 ± 0.08 MΩ (n = 47). The average maximum MET current
size was 1.50 ± 0.07 nA (n = 49), resulting in a maximum voltage
drop across the residual series resistance of 2.1 mV, a value sufficiently
small to not require any correction to quoted voltage values.
Dose response curves were fitted with the equation
=
+ [ ]
I
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1
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where IC is the control current in the absence of the compound, [B] is
the concentration of the blocking compound, KD is the half-blocking
concentration, and nH is the Hill coefficient. Permeation and block of
the MET channel for carvedilol and 13 were quantified by fitting a
two barrier−one binding site model to the fractional block curves, as
described in detail before.20,31 This model is similar to that used to
describe block of the MET currents by DHS7 but modified to allow
for Hill coefficients different from one.
Block of GTTR Loading into Mouse Cochlear Culture Hair Cells.
Coverslips were removed from the Maximow slide assemblies, placed
in a Perspex viewing chamber and immersed in 500 μL HBHBSS.
Cultures were treated with either 100 μM carvedilol, 100 μM of the
carvedilol derivative 13 or 1% DMSO as a control, with carvedilol and
13 being dissolved in this solvent. After 5 min incubation time at
room temperature, GTTR was added at a final concentration of 0.2
μM, and incubation was continued for a further 10 min. The culture
was washed three times with HBHBSS before live imaging on a Zeiss
Axioplan2 microscope. A 60× water immersion lens was used to take
images of both the apical and basal regions of the cochlea across a
time range from 14 to 24 min post-GTTR application. Three repeats
were conducted. For quantification, analysis was performed on images
from the mid-basal region, 24 min post-GTTR application. Ten cells
from the first row of OHCs central to the 1200 pixel image were
analyzed, as shown by the asterisk in Figure 16, obtaining intensity
values from a 40 × 40 pixel region of interest (ROI). Three
background ROIs were measured, averaged, and subtracted from each
individual cell value, which were then averaged and repeated across
three trials. One background ROI was taken from nonsensory HC
cellular space to account for any endocytic loading.
Statistics. All graphical representations display mean ± standard
error of the mean. Numbers above bars denote the number of
independent experimental replicates. One-way ANOVA was applied
followed by Tukey’s multiple comparison test, assuming normal
distribution of the data. For GTTR live imaging experiments, an
unpaired t-test was used. Significance was set at * = p < 0.05, ** = p <
0.01, and *** = p < 0.001.
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MET, mechanoelectrical transducer; AG, aminoglycoside;
ROS, reactive oxygen species; OHC, outer hair cell; IHC,
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